Mochida Pharmaceutical Co., Ltd. (TYO:4534)

Japan · Delayed Price · Currency is JPY

3,150.00

-25.00 (-0.79%)

Jun 19, 2026, 3:30 PM JST

6.96% (1Y)

Market Cap	111.67B +6.4%
Revenue (ttm)	116.95B +11.2%
Net Income	7.90B +39.0%
EPS	222.93 +39.0%
Shares Out	35.45M
PE Ratio	14.13
Forward PE	n/a
Dividend	85.00 (2.68%)
Ex-Dividend Date	Mar 30, 2026

Volume	86,100
Open	3,170.00
Previous Close	3,175.00
Day's Range	3,125.00 - 3,175.00
52-Week Range	2,859.00 - 3,965.00
Beta	0.09
Analysts	Hold
Price Target	3,200.00 (+1.59%)
Earnings Date	Aug 3, 2026

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and p... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1913

Employees 1,508

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4534

Full Company Profile

Financial Performance

In fiscal year 2026, Mochida Pharmaceutical's revenue was 116.95 billion, an increase of 11.21% compared to the previous year's 105.16 billion. Earnings were 7.90 billion, an increase of 39.01%.

Financial Statements